On January 3, 2025, IceCure Medical announced it received an Intention to Grant Notice from the European Patent Office for its invention titled 'Cryogenic System Connector.' This invention is designed to improve the safety and maintain the integrity of the cryogen used in the cryoablation procedure. The same invention was recently granted a patent in the United States, expanding IceCure's global intellectual property protection.
This patent relates to the next-generation XSense™ system and its cryoprobes, which have already received U.S. Food and Drug Administration clearance for all indications currently approved for ProSense®. The 'Cryogenic System Connector' technology is expected to enhance the efficiency and reliability of IceCure's cryoablation systems. This strengthens the company's position in the European market, where ProSense® is already sold by several key distributors.
IceCure's CEO, Eyal Shamir, highlighted the increased momentum in the growth of the company's intellectual property assets, reinforcing its global leadership in cryoablation. This patent protection is crucial for supporting and accelerating the market adoption of its advanced technologies across various indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.